Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Attorney Richard Cassin On FCPA’s Impact On Foreign Acquisitions And Competitor Snitching: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Pharmaceutical companies face stepped up scrutiny of acquisitions and the possibility that competitors will point fingers at suspected fraud in order to lessen their own enforcement actions and penalties.

You may also be interested in...



A Long Way Still For Corrupt Business Practices In China, India - Pharmaceutical Regulatory And Compliance Congress

SINGAPORE - Major Chinese pharma companies are eyeing acquisitions of companies in lucrative Western markets to establish a global foothold, according to industry observers

Foreign Corrupt Practices Act Raises Disclosure Dilemma For Internal Investigations

While companies are feeling pressure to voluntarily disclose potential violations of the U.S. Foreign Corrupt Practices Act, it may not always be the most prudent action, former government attorneys suggested at a recent meeting

J&J Takes The Lead In Settling SEC/DoJ Foreign Corrupt Practices Act Probe

Johnson & Johnson agreed to pay $70 million to resolve charges by the Securities and Exchange Commission and the Department of Justice that the company bribed doctors in several European countries to order or prescribe its products in violation of the Foreign Corrupt Practices Act

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

AP000837

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel